论文部分内容阅读
抗血小板治疗是心血管领域永恒的话题,全世界学者都努力在出血和血栓之间寻找平衡,对于新型抗血小板药物的研究亦从未停止。目前,阿司匹林与氯吡格雷的双重抗血小板治疗是急性冠状动脉综合征(ACS)患者经皮冠状动脉介入(PCI)治疗围手术期的标准化治疗方案,近年来新型P2Y12受体阻滞剂的出现对这一标准方案提出挑战。本文通过综述各种P2Y12受体阻滞剂抗血小板作用机制及临床特点的异同,为临床上新型P2Y12受体阻滞剂的应用及进一步研究提供理论依据。
Antiplatelet therapy is an eternal topic in the field of cardiovascular medicine. Scholars around the world are striving to find a balance between bleeding and thrombosis. Research on new anti-platelet drugs has never stopped. Currently, dual antiplatelet therapy with aspirin and clopidogrel is a perioperative standardization regimen for percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS). In recent years, the emergence of novel P2Y12 receptor blockers Challenge this standard program. This review summarizes the anti-platelet mechanism and clinical features of various P2Y12 receptor blockers, and provides a theoretical basis for the clinical application and further study of P2Y12 receptor blockers.